

PORCINE BASED ANTICOAGULANT IN PREGNANCY REVISITED: ANALYSIS AND DISCUSSION OF NATIONAL FATWA IN ALIGNED WITH ISTIHALAH FIQH CONCEPT IN CLINICAL PRACTICE

NurZaireena Zainalⁱ, Jameela Satarⁱⁱ, Irwan Mohd Subriⁱⁱⁱ& Muhammad Nasiruddin Asman^{iv}

ⁱSenior Lecturer,O&G Department, Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia. drzaireen@usim.edu.my

ⁱⁱHaematologyDepartment, Hospital Ampang. jsathar@hotmail.com

ⁱⁱⁱ Director, World Fatwa Management and Research Institute (INFAD), Universiti Sains Islam Malaysia. irwan@usim.edu.my

^{iv} Researcher, World Fatwa Management and Research Institute (INFAD), Universiti Sains Islam Malaysia. <u>nasznasiruddin@gmail.com</u>

<u>Article Progress</u> Received: 25 Oktober 2018

Revised: 2 December 2018

Accepted: 26 December 2018

ABSTRACT

Recent studies around the world have shown that there is an increment of maternal mortality due to the rising incidence of blood clot complication or commonly known as venous thromboembolism in pregnancies and during confinement. Women with high risk pregnancies are treated with low molecular weight heparin (LMWH) as the effective anti coagulant either during antenatal period or post delivery depending on their risk for certain duration. Thus, has shown to improve and reduce the maternal mortality and morbidity rate. Unfortunately, the usage of LMWH which are porcine in origin has raised a concern among Muslim health practitioner and public, although it is clinically proven to be the safest anti-coagulant treatment for pregnant women with complications following venous thromboembolism event. This article was meant to analyse the figh concept of istihalahbetween scholars and evidence, regarding the usage of porcine based LMWH among pregnant women. Figh method upon istihalah, references and content analysis; supported with more recent clinical evidences were analysed and elaborated regarding this issue and its clinical usage of LMWH upon pregnant mothers. There were unduly debate between Muslim scholars and Muslim health practitioners around the globe regarding the usage of porcine base LMWHas the best treatment in preventing and treating venous thromboembolism using LMWH. The istihalah concept has allowed many Muslim scholars in other countries to agree on the usage of LMWH in clinical practice. Nevertheless, Malaysian National Fatwa council has issued to forbid the usage of LMWH due to availability of other anticoagulant options. Yet; new evidences in which absent of porcine traces after manufacturing of LMWH proven safety profile of porcine base anticoagulant has emerged and has change the perspectives of clinical practice. These arguments hopefully able to facilitate the justification of istihalah concept in permissibility of LMWH usage in clinical practice among Muslim health practitioner and create public awareness.

Keywords: Maternal, pregnancies, istihalah, low molecular weight heparin, fiqh.

INTRODUCTION

The global maternal mortality rate has decreased tremendously over the last few decades as the advance development of medical technologies and improvement of health care services worldwide. The systematic health care programmes for pregnant mothers as well as increasing numbers of well equipped facilities and trained medical personnel along with health care providers have contributed to almost 50% dropped in the figures for maternal mortality. However, the numbers seems staticuntil the year 2015(Department of Statistic Malaysia, 2017).

Many efforts have been done to further decrease these figures as maternal mortality is one of the important components in the targeted 5th"*Malaysia Millenium Development Goal*". This is a very crucial parameter for a country's development whereby the development are measured by the "United Nations" (UN) from the ability to provide good health care system primarily the pregnant mothers and sustained good maternal and fetal outcome (United Nation Malaysia, 2015).

Although post partum haemorrhage was the number one killer for pregnant mothers in labour especially in the developing country, the figures seems decreasing and static. Yet, the current trend of obstetric thrombo-embolism seems to be on the rise. These thrombo-embolism events commonly occur in the lung (pulmonary embolism) and along the veins over the lower limbs (deep vein thrombosis) which very much pregnancy related. In United Kingdom, 89 percent of maternal death contributed by this condition between the year 2003-2005. Fortunately, the percentage dropped to 70 percent lower as soon as guidelines in managing the case were introduced, followed by intensive efforts in treating it using the anticoagulant drug therapy (Centre for Maternal and Child Enquiries (CMACE), 2011.Malaysia was among the country that had been using this anticoagulant therapy as treatment of this condition.

Generally, all pregnant women have a higher coagulable blood and almost stagnant blood flow in their body. This is very much contributed by the physiological changes of the pregnancy itself to accommodate the nutrition to the growing baby and to avoid the mother to bleed to death upon delivery. This normal physiological changes further thickened blood flow with presence of other few risk factors such as advance maternal age upon approaching the pregnancy, smoking, obesity and many other risk factors which are contributed by medical back ground and lifestyle (RCOG United Kingdom, 2015). Despite known risk factor, the early symptoms might not easily detected as pregnancy symptoms may mask the presentation such as feeling fatigue, shortness of breath and swollen legs. Thus screening of risk factors early in the pregnancy and early treatment is crucial and the main principle of the treatment. The current treatment is by using the low molecular weight heparin (LMWH) as anticoagulant to help in thinning the blood flow and diluting the clots among these pregnant mothers (RCOG UK, 2015 &MOH Malaysia 2013).

This article was written to further debate and discusses the usage of LMWH anticoagulant treatment in relation to the *'istihalah'* concept in Islamic *fiqh* jurisprudence. The discussion will be divided into two parts; the first part of discussion will include medical and health view and opinion in the usage of LMWH anticoagulant treatment. The

second part will be the discussion regarding the *'istihalah'* concept using the LMWH as treatment among Muslims patients and the application to our daily living.

THE USAGE OF LOW MOLECULAR WEIGHT HEPARIN IN OBSTETRIC MEDICINE


Various studies have been done upon the efficacy and safety profile upon pregnant mothers using LMWH as anticoagulant either as prophylactic or treatment dosage. These studies did review on many perspectives of the anticoagulant including the safety profile, embryopathy effect, feasibility, efficacy, potency, side effect and complication to both mother and baby. Not to mention the cost effectiveness of the medication and comparable to other types of anticoagulant. There were many types of anti coagulant drug available in the current market with wide range of price, availability, and efficacy and safety profile; yet, the usage in pregnancy and risk to the unborn child is the main concern. Furthermore, a pregnant woman undergone a lot of physiological changes to their physical, physiological and biochemical profile to the extent the bioavailability, and metabolism of drug may affect differently.Thus, this topic aimed to discuss in depth regarding the current anticoagulant specifically the LMWH treatment used among pregnant women.

Low molecular weight heparin (LMWH) is one of the common anticoagulant drugs used as blood thinning drug. It is called as low molecular weight heparin as the molecules were in smaller size as compared to the conventional un fractionated heparin drug. In Malaysia, there are two types of LMWH that is available for medical preparation, Enoxaparin Sodium (Clexane) and Tinzapain (Innohep) which are individually packed in a specialized syringe. These medications are used to be delivered under the subcutaneous layer of the skin by injecting with a needle. The usage of LMWH as blood thinning agent are highly recommended as compare to conventional usage of *unfractionaed heparin* due to better safety and stable pharmacokinetic profile. Thus less risk and complication to patients' especially pregnant mother (Ian A. G& Catherine NP, 2005).

Pharmacokinetic of Low Molecular Weight Heparin (LMWH)

Low molecular weight heparin (LMWH) is produced from chemical depolimerization using enzymes from the mucosa layer of the porcine small bowel. The chemical structure has higher anti-thrombotic and anti-coagulant properties as compared to unfractionated heparin. It binds to anti-thrombin II in cellular level where it inhibits the coagulation cascade activity; specifically clotting factor IIa and Xa. Thus, leading to thinning of blood by less aggregation of the platelets (Garcia DA, Baglin TP, Weitz JI&Samama MM, 2012). This activity triggered at the specific dosage given calculated according to patient's body weight. It is the safest anticoagulant in pregnancy due to its property and individual dose specific preparation (Sanofi.co.uk, 2011)

Figure 1: Chemical Structure OnLMWH(Enoxaparin)



Clinical Application of Low Molecular Weight Heparin (LMWH)

Anticoagulant has been used for various treatment of clotting disorders or even complication following blood clotting problems such as ischeamic heart disease or cerebrovascular accidents. Our discussion is more towards the usage in pregnancy and post partum period. Pregnant women are at higher risk of blood clotting problems as compared to normal population as the physiological changes in pregnancy itself causing them to become hypercoagulable. Thus, these young women at reproductive age are far more at risk to develop clotting problems which includes, pulmonary embolisms, ischaemic heart attack, cerebrovascular accidents, recurrent miscarriages, fetal growth restrictions and even death of the mother and unborn child.

Although pregnancy is a risk by itself, only some group of women will require treatment with anticoagulant. The obstetricians will need to assess these women and risk stratified them during their booking in first trimester to determine their requirement, indication and even calculated dosage. This is because, studies have shown there are women who are at higher risk of developing venous thromboembolism problems as compare to other pregnant women which include, previous history of thromboembolism, obesity, high parity and advanced maternal age. These women in the high risk group are predisposed to higher risk of mortality and morbidity to both mother and baby (RCOG UK, 2015 &MOH, Malaysia, 2013).

The usage of LMWH aredivided into two groups, prophylaxis treatment whereby the medication is used to prevent further complication of thromboembolism. Secondly, as the treatment dosage whereby the higher dose is given to treat a hypercoagulable state of the patient or to help to de-clogged the thrombosis itself. This is because the prophylaxis dose are lower than treatment dose, and it also depends on patient weight to reach treatment level. The duration of treatment also varies depending on prophylaxis or treatment dose and the risk factors involved. Definitely, detail assessment regarding the dosage and duration will be determined by the obstetrician base on written guidelines(RCOG UK, 2015) (MOH, Malaysia, 2013).

Patient with high risk factors such as certain inherited haematological or autoimmune disorders that are high risk to develop thrombosis events especially in pregnancy, theywill require certain prophylaxis dosage prior to embarking into the pregnancy accompany with close monitoring and counselling from the medical experts in preconception assessment. Same goes to women whom had cardiac valve replacement and on lifelong anticoagulant, the pregnancy should be planned and type of anticoagulant will be converted to LMWH due to better safety profile and risk of fetal anomaly on warfarin. As matter a fact, pregnancy is like a death sentence for them if it is not properly planned. The anticoagulant should be covered and adjusted to achieve safe motherhood, lower risk to the mother and baby. A successful pregnancy and healthy mother and baby are achievable with lower risk for complications using specifically tailored medication with LMWH (RCOG UK, 2015).

Yet, some women need the LMWH treatment only for certain short duration due to their background profile such as obesity, age more than 35 year old, smoking, prematurity, twin pregnancy and post operative delivery. Similarly to women whom previously had history of thrombosis, such as stroke (cerebrovascular events) or pulmonary embolism. The list of risk factors are listed according to studies and protocols made by the consensus among the medical and obstetric experts, Royal College Of Obstetric And Gynaecology, United Kingdom in 2015 (RCOG UK, 2015).

The protocol has a complete list of women with high risk medical profile requiring the LMWH treatment either as prophylaxis or as treatment dosage. It also stated the duration, type of best anticoagulant available and close monitoring required from antenatal to post natal period. These women will be divided into high risk, intermediate and low risk groups (RCOG United Kingdom, 2015& MOH, Malaysia, 2013). Otherwise, most women require the anti coagulant treatment only for short duration during post delivery due to the low risk assessment up to ten day post partum. These women are the ones in the low risk group such as delivery via caesarean section or due to age and high body mass index (RCOG UK, 2015&MOH, Malaysia, 2013).

There were many studies were done regarding the safety profile of all anticoagulant including LMWH in pregnancy, including the effectiveness and efficacy of preventing pulmonary embolism and deep vein thrombosis, recurrent miscarriages, intrauterine growth restricted babies and risk of intra-uterine death. Systematic reviews revealed that the LMWH had the best safety profile throughout pregnancy, in preventing the above incidents from the unfractionated heparin. Furthermore, it has fewer complications to the patients with lower risk for maternal mortality and morbidity, with higher successful live births (Ian A.G & Catherine N.P, 2005 & RCOG UK, 2015).

THE ISTIHALAH CONCEPT IN FIQH

The word *istihalah* originates from the Arabic word of *ha-wa-la* which means 'change'. Among the fiqh scholars, the discussion regarding *istihalah* are referred to the changes that occurs to the unclean and non-purified substance into a purified form(*al-Fayyumiyy*, N.d). Within this discussion, there are few other common Arabic words that is related to the discussion of istihalah among the previous Islamic scholars which include "*istihlak*" and "*inqilab al-cayn*" (Saadan Man, 2014).

According to one of the famous fiqh scholar in Shafi^ciyy'smadhhab, IbnHajar al-Haytamiyy (2001), *istihalah*ischanges that occurs to the physical structure or the physical condition only, yet there is no changes in '*dhat*'. Dr. Wahbah al-Zuhayliyy (1997) in his book, "*al-Fiqh al-IslamiyywaAdillatuhu*" had elaborated that istihalah is actually the process of the original '*dhat*' or a being from the '*najis*' or unclean into a new purified '*dhat*' or presence. He also refers the unlceaned form of something which is bound to be '*haram*' becoming something that is permissible in Islam due to the changes that it has undergone.

However, according to Ibn^cAbidin (1996), the changes or transformation of *istihalah* processcan occur in two conditions, whether it was fully transformed in total (*kulliyy*) or only some parts of the physical changes had occurred (*juz'iyy*). A simple example is that, in processing olive smeared with 'najis' to make soap and the process of alcohol turning into vinegar over time; both either naturally happened or through a specific synthetic process.

Associate Prof. Dr.Anisah Ab. Ghani (2014) in hes article entitle "*KonsepIstihalahdanHubungannyaDalamPenentuanHukumMakanan*", discussed regarding *istihalah's* theory in depth as she explained that it is a mixture between the unclean substance or known as 'najis' with a purified and clean substance which leads to changes in the '*dhat*' of the unclean substance becoming purified or both of these substance had mixed and inseparable.

While, Prof. Dato' PadukaDr.MahmoodZuhdiHj. Ab. Majid has given his theory which was similar as the theory of digestion system in the body. The digestion system is known to be able to breakdown and process any food or substance from its original form

and the final end product produce is totally different from its original form. During the *istihalah* process, there are many mechanical and non mechanical involve which occurs in stepwise processes before the final form of the substance is produced. A simple example in mechanical process is the process of transforming a dirty waste water becoming a totally purified water which is clean, yet suitable to drink. The process involved in transforming the clean purified water from the dirty waste is called *istihalah*. In another hand, *istihalah* in a non mechanical example is when a gambling money is given to the 'baitulmal' which this money will be later used and divides to the poor and needy (NorhidayahPuzi&Saadan Man, 2015).

Overview AmongMadhhabUpon Istihalah

Shafi^ciyyMadhhab

According to imam al-Shiraziyy (N.d) in his book "al-Muhadhdhab fi Fiqh al-Imam al-Shafi^ciyy":

ولا يطهر شيء من النجاسة بالاستحالة إلا شيئان: أحدهما جلد الميتة إذا دبغ وقد دللنا عليه في موضعه والثاني الخمر إذا استحالت بنفسها خلاً فتطهر بذلك

Which means, "Something that have been know impurity will not be purified by istihalah, unless in two things: (one): the skin of the dead animalsif it is cleaned (samak), and we have shown it in its place. (second): an alcohol if it was changed (istihalah) by itselfinto vinegar, it's considered pure".

While Ibn al-Naqib al-Shafi^ciyy (1982) written in his kitab "^cUmdat al-Salikwa^cUddat al-Nasik" did mention:

ولا يطهر شيء من النجاسات، إلا الخمر إذا تخلل، والجلد إذا دبغ، ونحساً يصير حيواناً.فإذا تخللت الخمر بغير إلقاء شيء فيها –إما بنفسها أو بنقلها من الشمس إلى الظل وعكسه أو بفتح رأسها– طهرت مع أجزاء الدَّنِّ الملاقية لها، وما فوقها مما أصابته عند الغليان، وإن ألقي فيها شيء فلا

Which means, "And it does not purify anything from filth (unclean), except liquor that turns into vinegar, and tanned (samak) skin, and something that turns into insect (such as the worm produced from the stool). If the changed of liquor without mixing anything on it -either by itself or changed the position from under the sun to shady place and vice versa or open the cap- It is still considered purify, but if it was thrown something into it (like gravel), then it is not pure".

HanafiyyMadhhab

Imam al-Zayla^ciyy (1984) in his kitab "Tabyin al-Haqa'iqSharhKanz al-Daqa'iqwaHashiyat al-Shalbiyy";

وَكُلُّ مَا لَا يَنْعَصِرُ بِالْعَصْرِ وَالْأَعْيَانُ النَّحِسَةُ تَطْهُرُ بِالِاسْتِحَالَةِ عِنْدَنَا وَذَلِكَ مِثْلُ الْمَيْتَةِ إِذَا وَقَعَتْ فِي الْمَمْلَحَةِ فَاسْتَحَلَّتْ حَتَّى صَارَتْ مِلْحًا وَالْعَذِرَةِ إِذَا صَارَتْ تُرَابًا أَوْ أُحْرِقَتْ بِالنَّارِ وَصَارَتْ رَمَادًا فَهِيَ نَظِيرُ الْخَمْرِ إِذَا تَخَلَّكُتْ أَوْ جِلْدِ الْمَيْتَةِ إِذَا دُبِغَتْ فَإِنَّهُ يُحْكَمُ بِطَهَارَتِهَا لِلِاسْتِحَالَةِ وَذَكَرَ فِي الْفَتَاوَى أَنَّ رَأْسَ الشَّاةِ لَوْ أُحْرِقَ زَالَ الدَّمُ يُحْكَمُ بِطَهَارَتِهِ، وَكَذَا الْبِلَّةُ النَّحِسَةُ فِي التَّنُورِ تَزُولُ بِالْإِحْرَاقِ

Which means, "An unclean thing will be purified by istihalah, as an example, the dead animal becoming a carcass on a salt pile until it is united with salt, and the animal stools that turn into soil or burn with fire to ashes. This condition is similar to the liquor that turns into vinegar or animal skins that are purified by the samakprocess due to its change (istihalah). It also mentioned in al-Fatawa that the blood on the head of goat when it is burned, it becomes purify. As well as the filth soil, if we made pottery using that soil then burned it on fire, then it considered purified".

While al-Imam MullaKhisro (N.d) in his kitab named"*Durar al-HukkamSharhGhurar al-Ahkam*" mentioned:

فَإِنَّ الْأَعْيَانَ تَطْهُرُ بِالِاسْتِحَالَةِ كَالْمَيْتَةِ إِذَا صَارَتْ مِلْحًا، وَالْعَذِرَةِ إِذَا صَارَتْ تُرَابًا، وَالْخَمْرِ خَلًّا وَنَحْوِ ذَلِكَ Which means, "The objects are purified with istihalah, like a carcass in the salt field (then its dissolved into salts), such as stool (shit) become soil, liquor into vinegar, then it was no longer

According tolbnNujaym (1968) discussion in his book, "al-Bahr al-Ra'iq", his view upon the issue of istihalah; istihalah is a process when something or a substance in its original form is considered as 'najis' or the unclean where there after undergone changes in its component becoming a pure 'dhat' in its substance. Similar example been given in the process where an alcoholic beverage undergone some changes and turns into vinegar which is pure. The fuqaha'salso had similar consensus upon this view. Similarly, if a dead body of a pig, falls into the basin of salts, and overtime degraded becomes salt. Thus the final product, which is the salt is consider as pure and clean. The same goes to the animal faeces, unclean body disposal taken and burnt into ashes, thus the burnt ashes is considered as pure too.

MalikiyyMadhhab

Among the fuqaha scholars of Malikiyy, they also do have similar views upon istihalah issue. Anything which if *najis* and unclean, undergone some changes and the final product is pure and good is considered as pure. While if a pure substance undergone some process and turns into *najis* and unclean, is *najis*. Al imam al-Dusuqiyy (N.d) in his book, *"Hashiyat al-Dusuqiyy-Ala al-Sharh al-Kabir"* wrote:

(وَمِسْكٌ) بِكَسْرٍ فَسُكُونٍ وَأَصْلُهُ دَمٌ انْعَقَدَ لِاسْتِحَالَتِهِ إِلَى صَلَاحٍ

Which means, "(A musk) its origin is blood and has undergone istihalah for good purpose (perfumery) is permiseble".

AndImam ^cUlaysh (1989) wrote's in his kitab:

claimed as a filth/impurified".

وَعِلَّةُ نَجَاسَةِ الْقَيْءِ الْمُتَغَيِّرِ الإسْتِحَالَةُ إِلَى فَسَادٍ

Which means, "The *cillah* (reason) of the impurity of vomiting is its change to something dirty and useless".

All of them including imam al-Dusuqiyy (N.d) in his book; "Hashiyat al-Dusuqiyy Ala al-Sharh al-Kabir", did mentioned:

Which means, "(Safra') a concentrated yellow water like za'faran concentrated that comes out from stomach and (balgham) or mucus, a slimy substance, usually not miscible with water, secreted by a mucous membrane or gland that comes out from chest or head of human. These two substances are considered clean as it come out from belly otherwise, the (cillah) reason of vomit is unclean (najs) as it is bad facade".

HanbaliyyMadhhab

One of the well known scholars, IbnQudamah (N.d) has written in his kitab"*al-Mughniyy*" as:

ظَاهِرُ الْمَذْهَبِ، أَنَّهُ لَا يَطْهُرُ شَيْءٌ مِنْ النَّحَاسَاتِ بِالِاسْتِحَالَةِ، إلَّا الْخُمْرَةَ، إذَا انْقَلَبَتْ بِنَفْسِهَا حَلَّا، وَمَا عَدَاهُ لَا يَطْهُرُ؛ كَالنَّحَاسَاتِ إذَا احْتَرَقَتْ وَصَارَتْ رَمَادًا، وَالْخِنْزِيرِ إذَا وَقَعَ فِي الْمَلَّاحَةِ وَصَارَ مِلْحًا، وَالدُّحَانِ الْمُتَرَقِّي مِنْ وَقُودِ النَّحَاسَةِ، وَالْبُحَارِ الْمُتَصَاعِدِ مِنْ الْمَاءِ النَّحِسِ إذَا اجْتَمَعَتْ مِنْهُ نَدَاوَةً عَلَى جِسْمٍ صَقِيلٍ ثُمَّ قَطَرَ، فَهُوَ بَخِسٌ. وَيَتَخَرَّجُ أَنْ تَطْهُرَ النَّحَاسَاتُ كُلُّهَا بِالِاسْتِحَالَةِ قِيَاسًا عَلَى الْخُمْرَةِ إذَا انْقَلَبَتْ، وَجُلُودِ الْمَيْعَةِ إذَا فَهُوَ بَحِسٌ. وَيَتَخَرَّجُ أَنْ تَطْهُرَ النَّحَاسَاتُ كُلُّهَا بِالِاسْتِحَالَةِ قِيَاسًا عَلَى الْخُمْرَةِ إذَا انْقَلَبَتْ، وَجُلُودِ الْمَيْعَةِ إذَا فَهُو بَخِسٌ. وَاللَّحَاسَةِ، وَاللَّهُ عَلَى اللَّعَاسَةِ، وَالْبُحَارِ الْمُتَصَاعِدِ مِنْ الْمَاءِ النَّحِسِ إذَا فَهُو بَخِسٌ. وَيَتَخَرَّجُ أَنْ تَطْهُرَ النَّحَاسَاتُ كُلُّهَا بِالِاسْتِحَالَةِ قِيَاسًا عَلَى الْخَمْرَةِ إذَا انْقَلَبَتْ، وَجُلُودِ الْمَيْعَةِ إذَا وَيَعَاسَ مَا عَلَى الْحُمْرَةِ إذَا مُعَنَّمَةِ إذَا فَهُو بَخِسٌ. وَاللَّهُ اللَّهُ اللَّهُ مَدَالَةُ إِنَا عَلَى الْكَابُ عَلَى الْخَابَيْنَةِ إذَا وَعَدْ نَهَى إِذَا رَائِقُلَبَتِ إِذَا لَقَتَعَنَى وَالْاقَوْلُ طَاهِرُ الْمَاءَ وَقَدْ نَهَى إِمَامُنَا – رَحْمَهُ اللَّهُ – عَنْ الْخَبْزِ فِي تَنُورٍ شُويَ فِيهِ خِنْزِيرٌ

Which means, "It is clear that something that najs will not purified by istihalah, except liquor, if it turns itself into vinegar, otherwise it is not purified; likefilth if burned and transform into ashes, pigs if it was dead on the salt field and then dissolving with the salt, and the smoke from the filth burner,water vapor that rising from the stool if it was accumulated over a cloth and then extracted, then it is najs. And all things that najs will be purified by the qiyas of istihalah in liquor transformed into vinegar, tanned animal skins and jallalah animals (animals that eat carcasses) that being locked in a cage. Our imam (scholar) also forbid us to baked bread in oven that used for roasting pork".

While Abu al-Khattab al-Kaluzaniyy (2004) in his kitab: *"al-Hidayah* AlaMadhhab al-Imam Abi Abdillah Ahmad bin Muhammad bin Hanbal al-Shaybaniyy" did mentioned: وَلاَ يَطْهُرُ شَيْءٌ مِنَ النَّحَاسَاتِ بِالاسْتِحَالَةِ، إِلاَّ الْخَمْرَ إِذَا انْقَلَبَتْ بِنَفْسِهَا، فَإِنْ خُلِّلَتْ لَمَ تَطْهُرُ. وَقِيلَ: تطهر وَلاَ يَطْهُرُ جَلْدُ مَا لاَ يُؤْكَلُ لَحُمُهُ بِالذَّكَاةِ، وَلاَ تَطْهُرُ جُلُوْدُ الْمَيْتَةِ بِالدِّبَاغِ فِي أَصَحِّ الرِّوَايَتَيْنِ، وَالأُحْرَى يَطْهُرُ مِنْها جِلْدُ مَا كَانَ طَاهِراً فِي حَالِ الْحَيَاةِ

Which means, "And it is not purified from uncleanness with istihalah, except alcohol if it changes naturally, otherwise it is not purified; and some said it is purified. The skin of animal is unclean if it's not slaughtered in Islamic ways. The skin of dead animal is uncleaneven even its undergone samak process according to strong opinion. And the second opinion said, it cleanses the skin of what was pure (tahir) in the case of it's life".

THE CLINICAL APPLICATION OF *ISTIHALAH* CONCEPT IN USING THE LOW MOLECULAR WEIGHT HEPARIN (LMWH)

The concept of *istihalah* as discussed according to the scholars as mentioned above has its own organized definition, to simplify it means any form of a substance that originally considered as the unclean or *najis* by the Islamic law, undergone certain process or changes and become pure as the final product is considered pure and clean. Base on this theory, this concept is very applicable in determining the discussion of clinical application of LMWH as the final end product which is clean and purified. This very important as LMWH is widely used including among the muslim community in treating their medical associated illness in pregnancy.

This medication is used widely due to its proven efficacy and safety profile in the pregnancy as prophylaxis and treatment to ensure healthy mother and baby. Yet the usage has raised concern among muslim communities. Knowing that it originates from porcine guts layers and synthesized into the medication. The process involved wasdepolimerization procedures where the polymers of proteins from this layers, broken into monomers which is the smallest particles and processed. This process can only be achieved under a very high temperature relatively comparable to any substance that is burnt by the heat.

In Malaysia, the usage of any porcine components within the food, medicine or even cosmetics used widely by the Muslims are seriously taken into and look upon by various Muslim religious bodies. Monitoring of *'halal'* quality including purity of the substance, analysis and even debates among the scholars. The National Fatwa Council had their *muzakarah* upon this sensitive issue of using the porcine based material which had undergone biotechnology process for certain usage by Muslims.

According to their 87th'*MuzakarahJawatankuasa Fatwa MajlisKebangsaanBagi Hal EhwalUgama Islam Malaysia (MJFMK)*' held on 23rd to 25th Jun 2009. A discussion was made specifically to discuss regarding the usage of LMWH (porcine based) which included '*Clexane'* 'Fraxiparine' as compared to 'Arixtra' synthetic base. The fatwa statement specifically mentioned that it is '*haram*' to use LMWH as there is the availability of other option, which is synthetic base anticoagulant for medicinal purpose.

DISCUSSION

After almost 10 years since the fatwa was released, there were more recent studies and updates around the world to further explore regarding the usage of LMWH in pregnancy and any possibilities of newer improved drugs. Unfortunately, there were increments of maternal death related to obstetric embolism to date. Principal cause of maternal death is still obstetric embolism in 2016 which was 23% in Malaysia (statistic on Causes of Death Malaysia, 2017). More guidelines and protocols supported with studies on drug safety and efficacy in preventing and treating obstetric embolism has been produced. The evidence has shown that LMWH, has been superior than its synthetic drug companion, *Arixtra*in pregnant patients.

Physiological changes in pregnancy has made these women becomes hypercoagulable than a normal non pregnant woman. With more women embarking into pregnancy at advance age beyond 35 years old and obese population, our risk factors for embolism in pregnancy has increased in general. Further increase in assisted reproductive techniques, surgical procedures and awareness of medical disease which are inherited conditions of abnormalities in the blood which make these women knocking to the door of death if they gets pregnant. Metabolism changes in a pregnant woman also differ making it very complex in deciding certain treatment, and safety risk to the unborn baby should be considered upon starting a medication. Unfortunately, ethically it is difficult for trials of new drug in pregnant woman.

LMWH has proven to show better safety profile due to its bigger molecular size than Arixtra (fondaparinux) it did not pass through the placenta to fetus. Studies has shown Fondaparinux presence in the fetal blood, although according to U.S. Food and Drug Administration (FDA) as category B, we still do not know the impact to the fetus as no proper studies were done. Furthermore, being a synthetic anticoagulant Fondaparinuxis not metabolised in the body, it requires 100% excretion from the kidney as compare to LMWH which is lower percentage of excretion. Unfortunately kidney excretion in pregnancy has some degree of changes to accommodate the baby. It function easily deteriorate especially women with medical problem in pregnancy such as high blood pressure. Failure of excretion leading to accumulation of this drug in the body resulting danger to both mother and baby as patient may complicate with bleeding problem to death. This condition is not reversible with any medication as it is synthetically produce. Unlike LMWH, it has better safety profile as there is an antidote in cases of bleeding using protamin sulphate. Fondaparinuxalso had longer half life, exposing to higher risk accumulation in the blood. This is the main reason LMWH is the best choice to use in pregnancy as prophylaxis and treatment.

Another factor that is perhaps considerable is that LMWH is far cheaper than *Fondaparinux*. Among all the expertise around the world and even in Malaysia, Obstetricians had gathered consensus that LMWH is far superior better used in pregnancy. More recent updates from the medical lab that is certified by renown religious body in Malaysia is that these LMWH were tested and there wereabsent porcine elements traced.LMWH has been used widely around the globe by almost all the Muslim obstetric consultants in Islam countries base on *istihalah* concept, similarly in our local setting despite the national fatwa given.

Properties	Enoxaparin Sodium (low molecular weight heparin, LMWH)	Fondaparinux
Source	Porcine intestinal mucosa layer	Synthetic polysaccharides
Molecular weight		
Dalton (Da)	4500	1728
Half life	5-7 hours	17-21 hours
Renal excretion	High (70%)	High (100%)
Excreted Placenta/	No/ not known but safe in	Not known
breast milk	breast feeding as it is not in	
(RCOG guidelines)	active form	
Metabolised	Depolymerisation	Not metabolized
Antidote	Reversed with protamine	Not available
	sulphate	
Category in usage to		
pregnant mother	Category B	Category B

Figure 2: Comparison Table Between Anticoagulant And Its Properties

(US FDA)		
	(US FDA)	

*Category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and

there are no adequate and well-controlled studies in pregnant women.

However, the statement above did not meant that these doctors were against the fatwa council. The Islamic medical community are aware regarding this matter and trying to find further prove to help in treating patients and honouring the *deen*. Decision made was always following *maqasid of syariah*, thus according to Dr. Suhazeli Abdullah (2016) as family medicine specialist regarding the usage of LMWH and the fatwa; as much that he agreed with it. The vailability and feasibility of the medicine should also be considered especially in *darurah or medical emergency, or there were no alternative as good as it is available*. A discussion regarding this issue was made between him and associate Professor Dr.Basri Ibrahim in venous thromboembolism seminar (Tabung Haji Hotel on the 3rd August, 2016) it is permissible usage for pregnant women base on all the safety profile, efficacy and feasibility to date.

Thus, base on all the evidence discussed as above, this review would like to recommend the *hukum*as the following:

- 1. Base on the clinical studies and data available; the usage of LMWH in pregnant women is permissible.
- 2. The recommendation should be bound to the rules it is really indicated as been assessed by the consultant obstetrician and there were no other similar drug with similar safety profile and efficacy.

The recommendation were made base on the evidence as follows:

- 1. Scientific evidence has proven that LMWH*Enoxaparin Sodium* (*Clexane*) which was mentioned in the fatwa was far superiorthan*Fondaparinux* (*Arixtra*).
- 2. LMWH has very minimal side effects and possible complications compare to than *Fondaparinux (Arixtra*).
- 3. According to Fiqh methodfiqh "al-HajahTunazzalManzilat al-Darurah^cAmmatanKanat aw Khassah" which means Al-Hajah (the necessity) equivalent to the darurah status either it is general use or specific in certain condition; al-hajahwith justification(al-taysir) and feasibility (al-tashil) to use whatever is required. This category is slightly lower than the darurah of fatality (Al-Zuhayliyy, Muhammad, 2006&AlBurnu, 1996). As darurah is considered as the reference pointbetween halal and haram, thus the justification includes al-hajah. This is base on Shafi^ciyyatauHanbaliyy scholars in istihalah issue al-hajahis permissible although it was not a true darurah, especially in the usage of LMWH in pregnancy.
- 4. According to the expert opinion, in this case the obstetricians and medical consultantsconcensus. According toDr. Adnan Azayzah (2006), the expert opinion and decision of the usage must be from the person with the verified qualifications, experience and vast knowledge in the related field whereby he is the point of reference of others. Imam al-Nawawiyy (1991), al-Zayla^ciyy (1982), al-Kasaniyy (1986), al-Mawwaq (1994) danIbnMuflih (1997) mentioned the same thing in their books. Therefore; the opinion of the obstetricians should be considered in this issue.

5. The raised issue regarding porcine based LMWH and *istihalah*is a fiqh arguments or *khilaf*in the*fiqh*concept. It was not an issue base on Hanafiyy or Malikiyy scholars as *istihalah* is well accepted. Yet, according to Shafi^ciyy scholars which is the majority in our country, atauHanbaliyy; we would like to propose permissible with terms and conditions as mentioned in the discussion base on *al-hajah*.

Similar istihalah concept has been used and applied in other Muslim countries by their religious body. As example, the Singaporean Islamic body (MajlisUgama Islam Singapura) in the usage of porcine based trypsin enzyme used for vaccination preparation. The enzyme was the safest method to produce the vaccine, which then after undergone many procedures until the final vaccine product only had 0.001% trace of porcine element. Thus, it is permissible base on *istihalah*fiqh concept to use this vaccine (NaziruddinMohdNasir, N.d). Similar concept by Dar al-Ifta' al-Misriyyah in producing fatwa upon the permissibility of using any food with presence of non halal elements (porcine or non slaughtered animals) which undergone many process and become purified. (<u>dar-alifta.org</u>.n.d).

CONCLUSION

The *istihalah* concept is very much relevant *fiqh* method to be used these days especially in many products or substance with non halal or unclean elements which had undergone many stages of process until purified. This is concurrent with the technology advancement in treating and improving health among mankind. Yet the application should be carefully looked upon by Muslim scholars so that it will not be too liberal or too conservative in making decision (Zaharuddin Abdul Rahman, 2015).

After thorough discussion, reviewing the new emerging evidences which clearly shows the benefit and higher safety profile of LMWH to be use among selected pregnant women with risk of venous thromboembolim as prevention and debates between scholars, the usage of porcine based LMWH can be permissible among selected pregnant women women with risk as preventive medicine using the *istihalah* method.

However, as it is against the previous national fatwa statement, a consensus between the muslim scholars and medical expert are very much obliged to revise it and todecide the *istihalah* concept and its *hukum*upon this matter as more evidence and data have emerged. Perhaps more solutions can be offered on every new issue similar as our discussion.

REFERENCE

- Abu al-Khattab al-Kaluzaniyy, Mahfuz bin Ahmad bin al-Hasan. 2004. *al-Hidayah*^cAlaMadhhab al-Imam Abi^cAbdillah Ahmad bin Muhammad bin Hanbal al-Shaybaniyy. N.pl: Mu'assasatGharras li al-Nashrwa al-Tawzi^c.
- AizatJamaluddin& Wan Jasimah Wan Mohamed. 2008. TeoriIstihalahMenurutPerspektif Islam danSains: AplikasiTerhadapBeberapaPenghasilanProdukMakanan. JurnalSyariah. jil. 1. Bil 1. Pp. 169-194.
- AsrorunNi'amSholeh. 2005. Jaminan Halal PadaProdukObat: Kajian Fatwa MUI danPenyerapannyaDalam UU JaminanProduk Halal. JurnalSyariah 3. Nov 2015.
- AluBurnu, Muhammad Sidqiyy bin Ahmad bin Muhammad. 1996. Al-Wajiz fi Idah*Al-Qawa^cid al-Fiqhiyyah al-Kulliyyah*. Beirut: Mu'assasat al-Risalah.

- Dempfle C-EH. N.d.*Minor Transplacental Passage OfFondaparinux In Vivo*. New England Journal of Medicine. 350: 1914-1915. No. 18. 29 Apr.
- al-Dusuqiyy, Muhammad bin Ahmad bin ^cArafah al-Malikiyy. N.d.*Hashiyat al-Dusuqiyy^cAla al-Sharh al-Kabir*. N.pl: Dar al-Fikr.
- al-HanbaliyyBadr al-Din Abu ^cAbdillah Muhammad bin ^cAliyy. 1985. *Mukhtasar al-Fatawa al-Misriyyah Li IbnTaimiyyah*. Beirut: Dar al-Kutub al-^cIlmiyyah.
- al-Fayyumiyy, Abu al-cAbbas Ahmad bin Muhammad cAliyy al-Muqriyy. N.d.*al-Misbah al-Munir fi Gharib al-Sharh al-Kabir*. Beirut: Dar al-Kutub al-cIlmiyyah.
- <u>Geno J. Merli, James B. Groce</u>. 2010. *Pharmacological and Clinical Differences Between Low-Molecular-Weight Heparins*. P. T. Feb. 35 (2): 95-105.
- al-Ghananim, Qadhdhafiyy Izzat. 2008. *al-IstihalahwaAhkamuha fi al-Fiqh al-Islamiyy*. Amman: Dar al-Nafa'is.
- Gomez- Outes et al. 2014.Direct Oral Anticoagulants In The Treatment Of Venous Thromboembolism, With A Focus On Patients With Pulmonary Embolism. VHRM.2014:10.
- Ibn^cAbidin, Muhammad Amin. 1906. *al-Durr al-MukhtarSharhTanwir al-AbsarwaBihamishihiHashiyahIbn^cAbidin. Jil.* 1. N.pl.: Maktabat al-^cUthmaniyyah.
- IbnHazm, Abu Muhammad ^cAli bin Ahmad IbnSa^cid al-Andalusiyy. 1988. *Al-Muhalla*. Jil.1. Beirut: Dar al-Kutub al-^cIlmiyyah.
- IbnMuflih, Abu Ishaq, Burhan ad-Din. 1997. *Al-Mubdi^c fi Sharh al-Muqni^c*. Beirut: Dar al-Kutub al-^cIlmiyyah.
- Ibn al-Naqib, Shihab al-Din Ahmad binLu'lu' bin ^cAbdillah al-Rumiyy al-Shafi^ciyy. 1982. *^cUmdat al-Salikwa^cUddat al-Nasik*. Qatar: al-Shu'un al-Diniyyah.
- IbnNujaym, Zayn al-Din bin Ibrahim. 1998. *al-Bahr al-Ra'iq*. Beirut: Dar al-Kutub al-Ilmiyyah.
- IbnQudamah, Muwaffaq al-Din ^cAbdullah bin Ahmad bin Muhammad. N.d.*al-Mughniyy*. N.pl: Maktabat al-Qahirah.
- IbnTaymiyyah, Abu al-cAbbasTaqiyy al-Din Ahmad IbnAbdHalim. N.d. al-Fatawa al-Kubra li IbnTaymiyyah. Jil.1. Beirut: Dar al-Macrifah.
- Al-Kasaniyy, Abu Bakar bin Mas^cud bin Ahmad. 1986. *Bada'i^c al-Sana'i^c fi Tartib al-Shara'i^c*. Beirut: Dar al-Kutub al-^cIlmiyyah.
- Mahmud Isma^cil Muhammad Mish^cal. N.d.*Athar al-Khilaf al-Fiqh fi al-Qawa^cid al-MukhtalafFihiWaMadaTatbiquha fi al-Furu^c al-Mu^casirah*. Egypt: Dar al-Salam.
- Al-Mawwaq, Abu ^cAbdullah Muhammad bin Yusuf bin Abu al-Qasim. 1994. *Al-Tajwa al-Iklil li Mukhtasar Khalil*. Beirut: Dar al-Kutub al-^cIlmiyyah.
- MohdIzharAriffMohdKashim. 2012. PenentuanHukumMakananUbahSuaiGenetik (GMF) BerasaskanHaiwan.Ph.D Thesis.FakultiPengajian Islam, UniversitiKebangsaan Malaysia.
- Muhammad Rawwas. Qal^cahjiyy.1996. *Mu^cjamLughat al-Fuqaha'*. Beirut. Dar al-Nafa'is.
- MullaKhisru, Muhammad binFaramiriz bin ^cAliyy. N.d.*Durar al-HukkamSharhGhurar al-Ahkam*.N.pl: Dar Ihya' al-Kutub al-^cArabiyyah.
- Al-Nawawiyy, Abu ZakriyyaMuhy al-Din YahyabinSharaf. 1991. Rawdat at-Talibinwa^cUmdat al-Muftin. Beirut: Al-Maktab Al-Islamiyy.
- NazihHammad. 2004. al-Mawad al-MuharramahWa al-Najisah fi al-Ghidha' wa al-Dawa'.Damsyiq: Dar al-Qalam
- NorhidayahPuzi&Saadan Man. 2015. *Analisis Fatwa-Fatwa Bone China DaripadaPerspektifHukum Islam*. JurnalPengurusan Dan Penyelidikan Fatwa. Vol. 5.

- Prevention &Treatment of Venous Thromboembolism, Malaysia Clinical Practised Guidelines.MOH/P/PAK 246.13 (GU).
- al-Shiraziyy, Abu Ishaq Ibrahim bin ^cAliyy bin Yusuf. N.d.*al-Muhadhdhab fi Fiqh al-Imam al-Shafi*^c*iyy*. N.pl: Dar al-Kutub al-^cIlmiyyah.
- ^cUlaysh, Muhammad bin Ahmad bin Muhammad al-Malikiyy. 1989. *Manh al-JalilSharhMukhtasar Khalil*. Beirut: Dar al-Fikr.

Zaharuddin Abdul Rahman. 2015. FiqhMedik. Selangor: PTS.

- Al-Zayla^ciyy, Fakhr al-Din. 1892. *Tabyin al-Haqa'iqSharhKanz al-Daqa'iq*. Cairo: al-Matba^cah Al-Kubra Al-Amiriyyah.
- Zulkifli Mohammad Al-Bakri. 2014. *Khinzir: PenciptaandanHukum-Hukum.* Nilai: PustakaCahayaKasturi (PCK).
- al-Zuhayliyy, Wahbah. 1997. al-Fiqh al-IslamiyywaAdillatuhu. Jil. 7. Dimashq: Dar al-Fikr.
- al-Zuhayliyy, Muhammad. 2006. *Al-Qawa^cid al-FiqhiyyahwaTatbiqatuha fi al-Madhahib al-Arba^cah*. Dimashq: Dar al-Fikr.

Internet

- Adnan ^cAzayzah. 2006. Qawl al-KhabirwaHujjiyyatuhu fi Ithbat al-^cAyb al-Mujib li Faskh^cAqd al-Nikah. Nadwat al-Qada' al-Shar^ciyy fi al-^cAsr al-Hadir: al-Waqi^cwa al-Amal. Jami^cat al-Shariqah.file:///C:/Users/admin/Downloads/ShrjaLabel09-04-2013-09-39-53.pdf(accessed on 6th June 2017).
- AnisahAbdGhani. 5 Jun 2014. *KonsepIstihalahdanHubungannyaDalamPenentuanHukumMakanan*.https://helikmedia.w ordpress.com/2014/06/05/konsepistihalahdanhubungan

nyadalampenentuanhukummakanan/(accessed on 5th May 2017).

- Centre for Maternal and Child Enquiries (CMACE). *Saving Mothers' Lives: Reviewing Maternal Deaths To Make Motherhood Safer: 2006–08.* The Eighth Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011;118 (Suppl. 1):1-203.
- Fatwa on Food and Drink: What is The Ruling Regarding Eating Products Made Out of Gelatin?http://dar-alifta.org/Foreign/ViewFatwa.aspx?ID=6891(accessed on 4th May 2017).
- FDA
 Pregnancies
 Categories,
 Drugs.com
 retrieved
 from

 https://www.drugs.com/pregnancy-categories.html
 (accessed on 1st August 2018).
 1st August 2018).

GarisPanduanBersamaKawalanUbat-UbatDalam Islam. http://www.islam.gov.my/rujukan/garis-panduan/52-garis-panduan-bersamakawalan-ubat-ubat-dalam-islam(accessed on 9th May 2017).

- <u>Garcia DA</u>, <u>Baglin TP</u>, <u>Weitz JI</u>&<u>Samama MM</u>; Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.<u>Chest.</u> 2012 Feb;141 (2 Suppl):e24S-e43S. doi: 10.1378/chest.11-2291. (accessed 22nd January, 2019)
- Greentop guidelines no. 37a; Reducing The Risk Of Venous Thromboembolism During Pregnancy And ThePuerperium; April 2015; 1-40. https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf.
- Greentop guidelines no. 37b; Thromboembolic Disease In Pregnancy And ThePuerperium: Acute Management. April 2015, 1-32. https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37b.pdf.

Ian A. Greer & Catherine Nelson Piercy.*Low- Molecular- Heparin ForThromboprophylaxis and Treatment of Thromboembolism in Pregnancy: a Systematic Review of Safety and Efficacy.* Volume 106 number 2.www.blood journal.org(accessed on 4th May 2017).

Innohep.<u>http://www.rxlist.com/innohep-drug.htm</u> (accessed on 4th May 2017).

KompilasiPandanganHukumMuzakarahJawatankuasa Fatwa MajlisKebangsaanBagi Hal EhwalUgama Islam Malaysia. 2015. BahagianPengurusan Fatwa, JabatanKemajuan Islam

Malaysia.http://www.islam.gov.my/images/ePenerbitan/KOMPILASI_MUZAKARA H_MKI_2016.pdf(accessed on9thMay 2017).

Laporan Maternal mortality in 1990-2015'WHO, UNICEF, UNFPA, World Bank Group, and United Nations Population DivisionMaternal Mortality Estimation Inter-Agency Group MALAYSIA.

http://apps.who.int/iris/bitstream/10665/194254/1/9789241565141_eng.pdf.

Malaysia Millennium Development Goals 2015 Report.Lampiran 1, Malaysian Millenium Development Goal Indicators, United Nation Malaysia <u>http://www.my.undp.org/content/malaysia/en/home/library/mdg/malaysia-</u> <u>millennium-development-goals-2015-report-.html</u> (accessed on 4th May 2017).

NurulHalawatiAzhari. N.d.IstihalahPenentu Halal atauTidak.http://kpdnkk.bernama.com/newsBm.php?id=538902 (accessed on 8th May 2017).

- Saadan Man. 2014. Contemporary IjtihadOn Issue of Istihalah: A Comparative Study Between Fatwas by Middle East Jurist and Malaysian National Fatwa Council. http://ukmsyariah.org/terbitan/wp-content/uploads/2015/10/20-Saadan-Man.pdf.
- Statistic on Causes of Death Malaysia 2017. Department of statistic Malaysia retrieved from

https://dosm.gov.my/v1/index.php?r=home/index&menu_id=b2ROaWpITmQ5NnA vMHVmRjRkZzlBQT09(accessed on 1stAug 2018)

- Suhazeli Abdullah. 2016. *Penggunaan Enoxaparin (Clexane) VsFondaparinux (Arixtra); Haram Vs Halal*.http://suhazeli.com/wp/?p=1994 (accessed on 9thMay 2017).
- Summary Of Product Characteristics. <u>http://www.sanofi.co.uk/products/ClexaneFortes_SPC.pdf</u> (accessed on 4th May 2017).
- Lukmanul Hakim RaihGelar PHD Dari Belanda- MajelisUlama Indonesia.21 Feb 2017. <u>http://mui.or.id/id/berita/lukmanul</u>hakimraihgelarphddaribelanda/ (accessed on 4th May 2017).

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-

<u>Product Information/human/000403/WC500027746.pdf</u> (accessed on 31thMay 2017). <u>www.pharmacy.gov.my/v2/en/apps/</u>drug-price (accessed on 1st June 2017).